Varicella-zoster Virus Glycoprotein E
recombinant, E. coli
For in vitro use only!
Shipping: shipped on gel packs
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Purity: > 95 % (SDS-PAGE)
Form: liquid (Supplied in 60 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.25% Sarkosil, 10 mM Glutathione and 50% glycerol)
Antigen in ELISA and Western blots, excellent antigen for detection of VZV with minimal specificity problems.
The protein contains the VZV-gE immunodominant regions, amino acids 48-135. The protein is purified by proprietary chromatographic technique.
Background: Varicella-zoster virus (VZV) is an extremely cell-associated alpha herpesvirus. It interacts with cell surface heparan sulfate proteoglycans during virus attachment. VZV-gE is a glycoprotein that plays an active or supportive role in VZV cell membrane fusion. VZV-gE was found to enhance the fusogenic potential of VZV gB.
Specificity: Immunoreactive with sera of VZV-infected individuals.
Maresova et al. (2005) Incorporation of three endocytosed varicellazoster virus glycoproteins, gE, gH, and gB, into the virion envelope. J. Virol. 79:997.
Taha et al. (2004) Are false negative direct immunfluorescence assays caused by varicella zoster virus gE mutant strains? J. Med. Virol. 73:631.
Pasieka et al. (2004) Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. J. Virol. 78:2884.
Mo et al. (2002) The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology. 304:176.
Kenyon et al. (2002) Phosphorylation by the varicella-zoster virus ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-Golgi network or recycles to the cell membrane. J. Virol. 76:10980.
Jaquet et al. (2002) Immunogenicity of a recombinant varicellazoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine. 20:1593.